More on PRTC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.42 |
|
|||
| Open | $17.42 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $17.42 | ||||
| Day Low | $17.42 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 98 | ||||
- PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
- Celea Therapeutics to present Phase 3 IPF trial data at ERS Congress
- Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
- Celea Therapeutics begins Phase 3 trial of deupirfenidone for IPF
- Celea Therapeutics doses first patient in phase 3 IPF drug trial
- PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
- PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
- PureTech Health: Results of Annual General Meeting
Entities mentioned with PRTC
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- S1 | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- SPAC | View Related Stories »
- IPO | View Related Stories »
- Show More...
